JP2021193108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021193108A5 JP2021193108A5 JP2021145468A JP2021145468A JP2021193108A5 JP 2021193108 A5 JP2021193108 A5 JP 2021193108A5 JP 2021145468 A JP2021145468 A JP 2021145468A JP 2021145468 A JP2021145468 A JP 2021145468A JP 2021193108 A5 JP2021193108 A5 JP 2021193108A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023131211A JP2023159230A (ja) | 2016-04-15 | 2023-08-10 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1606631.8 | 2016-04-15 | ||
| GB201606631 | 2016-04-15 | ||
| GB201619277 | 2016-11-14 | ||
| GB1619277.5 | 2016-11-14 | ||
| JP2018554114A JP6943876B2 (ja) | 2016-04-15 | 2017-04-18 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554114A Division JP6943876B2 (ja) | 2016-04-15 | 2017-04-18 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131211A Division JP2023159230A (ja) | 2016-04-15 | 2023-08-10 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021193108A JP2021193108A (ja) | 2021-12-23 |
| JP2021193108A5 true JP2021193108A5 (2) | 2022-02-08 |
Family
ID=58633035
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554114A Active JP6943876B2 (ja) | 2016-04-15 | 2017-04-18 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
| JP2021145468A Pending JP2021193108A (ja) | 2016-04-15 | 2021-09-07 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
| JP2023131211A Pending JP2023159230A (ja) | 2016-04-15 | 2023-08-10 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554114A Active JP6943876B2 (ja) | 2016-04-15 | 2017-04-18 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131211A Pending JP2023159230A (ja) | 2016-04-15 | 2023-08-10 | Ｒｅｔキナーゼ阻害剤としての複素環化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10954241B2 (2) |
| EP (2) | EP3442980B1 (2) |
| JP (3) | JP6943876B2 (2) |
| KR (3) | KR102706837B1 (2) |
| CN (2) | CN109195972B (2) |
| AU (3) | AU2017250448C1 (2) |
| BR (2) | BR122023026297A2 (2) |
| CY (1) | CY1124478T1 (2) |
| DK (1) | DK3442980T3 (2) |
| ES (1) | ES2886587T3 (2) |
| HR (1) | HRP20211362T1 (2) |
| HU (1) | HUE056135T2 (2) |
| IL (3) | IL289793B2 (2) |
| LT (1) | LT3442980T (2) |
| MX (2) | MX387394B (2) |
| PL (1) | PL3442980T3 (2) |
| PT (1) | PT3442980T (2) |
| RS (1) | RS62322B1 (2) |
| RU (1) | RU2742115C2 (2) |
| SG (2) | SG10201911665UA (2) |
| SI (1) | SI3442980T1 (2) |
| SM (1) | SMT202100538T1 (2) |
| WO (1) | WO2017178844A1 (2) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| WO2017178844A1 (en) * | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| SI3442535T1 (sl) * | 2016-04-15 | 2023-01-31 | Cancer Research Technology Limited | Heterociklične spojine kot zaviralci RET-kinaze |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| EP3740490A1 (en) * | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| PE20210096A1 (es) | 2018-04-03 | 2021-01-12 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret |
| IL277408B2 (en) * | 2018-04-05 | 2024-08-01 | Merck Patent Gmbh | Heteroaryl compounds as IRAK type II inhibitors and their use |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| MX2021003904A (es) | 2018-10-05 | 2021-10-26 | Annapurna Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |
| WO2020200316A1 (zh) * | 2019-04-03 | 2020-10-08 | 南京明德新药研发有限公司 | 作为ret抑制剂的吡唑并吡啶类化合物及其应用 |
| JP7732668B2 (ja) * | 2019-08-05 | 2025-09-02 | 北京志健金瑞生物医▲薬▼科技有限公司 | 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途 |
| US12565481B2 (en) | 2020-02-20 | 2026-03-03 | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory | 6,7-dimethoxy-3-(pyridin-2-yl)quinoline compounds for inhibiting RET |
| EP4146654A1 (en) * | 2020-05-07 | 2023-03-15 | Adorx therapeutics Limited | Antagonists of the adenosine a2a receptor |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CN113214294A (zh) * | 2020-06-10 | 2021-08-06 | 深圳铂立健医药有限公司 | 三环化合物、药物组合物及其应用 |
| KR20230104781A (ko) | 2020-10-05 | 2023-07-10 | 인라이븐 테라퓨틱스, 인크. | Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물 |
| TWI887510B (zh) * | 2020-12-22 | 2025-06-21 | 美商基利科學股份有限公司 | 6-取代之吲哚化合物 |
| TWI838670B (zh) * | 2020-12-22 | 2024-04-11 | 美商基利科學股份有限公司 | 經取代之吲哚化合物 |
| KR20230171469A (ko) | 2021-04-16 | 2023-12-20 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| EP4415718A1 (en) * | 2021-10-15 | 2024-08-21 | Stemline Therapeutics Inc. | Inhibitors of mutant ret kinases for use in treating cancer |
| WO2024151519A2 (en) * | 2023-01-09 | 2024-07-18 | University Of Florida Research Foundatin, Incorporated | Pparg modulators |
| AR133526A1 (es) * | 2023-08-09 | 2025-10-08 | Daewoong Pharmaceutical Co Ltd | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0322779A3 (en) | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US6383790B1 (en) * | 1999-01-11 | 2002-05-07 | Princeton University | High affinity protein kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| EP1831225A2 (en) | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| WO2006092430A1 (de) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
| ES2365869T3 (es) * | 2005-11-17 | 2011-10-11 | OSI Pharmaceuticals, LLC | COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR. |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| ES2545907T3 (es) | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| JP2008063278A (ja) | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | １−ピリジン−４−イル−インドール類の製造方法 |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| US20090274698A1 (en) * | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX2010007419A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| EP2252293B1 (en) * | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| BRPI0915231A2 (pt) * | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| NZ599830A (en) | 2009-11-05 | 2014-08-29 | Rhizen Pharmaceuticals Sa | Novel kinase modulators |
| EP2528919B1 (en) | 2010-01-28 | 2016-11-02 | University of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
| US9765037B2 (en) | 2010-01-28 | 2017-09-19 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases |
| UY33288A (es) * | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| US20130296316A1 (en) | 2010-07-09 | 2013-11-07 | Michael P. Pollastri | Antiparasitic Agents Based On mTOR Inhibitors |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| JP6047149B2 (ja) | 2011-05-04 | 2016-12-21 | インテリカイン， エルエルシー | 併用の医薬組成物およびその使用 |
| EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
| CA2846496C (en) * | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| WO2013070976A1 (en) | 2011-11-08 | 2013-05-16 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US9738610B2 (en) | 2012-09-24 | 2017-08-22 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| GB201217285D0 (en) | 2012-09-27 | 2012-11-14 | Univ Central Lancashire | Indole derivatives |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| CA2922044A1 (en) | 2013-10-18 | 2015-05-14 | Medivation Technologies, Inc. | Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk) |
| CA2922058A1 (en) | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| GB201321146D0 (en) * | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| KR102562866B1 (ko) | 2014-11-14 | 2023-08-04 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체 |
| CA2974702C (en) | 2015-01-26 | 2023-10-10 | University Of Washington | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases |
| WO2017027883A1 (en) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
| JP7337502B2 (ja) * | 2015-09-16 | 2023-09-04 | ロクソ オンコロジー， インコーポレイテッド | がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体 |
| WO2017160717A2 (en) | 2016-03-15 | 2017-09-21 | Memorial Sloan Kettering Cancer Center | Method of treating diseases using kinase modulators |
| SI3442535T1 (sl) * | 2016-04-15 | 2023-01-31 | Cancer Research Technology Limited | Heterociklične spojine kot zaviralci RET-kinaze |
| WO2017178844A1 (en) * | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
-
2017
- 2017-04-18 WO PCT/GB2017/051076 patent/WO2017178844A1/en not_active Ceased
- 2017-04-18 EP EP17719687.0A patent/EP3442980B1/en active Active
- 2017-04-18 KR KR1020227013172A patent/KR102706837B1/ko active Active
- 2017-04-18 SM SM20210538T patent/SMT202100538T1/it unknown
- 2017-04-18 RS RS20211115A patent/RS62322B1/sr unknown
- 2017-04-18 DK DK17719687.0T patent/DK3442980T3/da active
- 2017-04-18 BR BR122023026297-2A patent/BR122023026297A2/pt not_active Application Discontinuation
- 2017-04-18 BR BR112018071097-0A patent/BR112018071097B1/pt not_active IP Right Cessation
- 2017-04-18 SG SG10201911665UA patent/SG10201911665UA/en unknown
- 2017-04-18 HR HRP20211362TT patent/HRP20211362T1/hr unknown
- 2017-04-18 PT PT177196870T patent/PT3442980T/pt unknown
- 2017-04-18 EP EP21172597.3A patent/EP3960180A1/en active Pending
- 2017-04-18 JP JP2018554114A patent/JP6943876B2/ja active Active
- 2017-04-18 RU RU2018138471A patent/RU2742115C2/ru active
- 2017-04-18 IL IL289793A patent/IL289793B2/en unknown
- 2017-04-18 KR KR1020247030356A patent/KR20240142568A/ko not_active Withdrawn
- 2017-04-18 US US16/093,854 patent/US10954241B2/en active Active
- 2017-04-18 MX MX2018012609A patent/MX387394B/es unknown
- 2017-04-18 PL PL17719687T patent/PL3442980T3/pl unknown
- 2017-04-18 KR KR1020187032842A patent/KR102390578B1/ko not_active Expired - Fee Related
- 2017-04-18 ES ES17719687T patent/ES2886587T3/es active Active
- 2017-04-18 IL IL297192A patent/IL297192A/en unknown
- 2017-04-18 HU HUE17719687A patent/HUE056135T2/hu unknown
- 2017-04-18 SI SI201730892T patent/SI3442980T1/sl unknown
- 2017-04-18 SG SG11201808878UA patent/SG11201808878UA/en unknown
- 2017-04-18 LT LTEPPCT/GB2017/051076T patent/LT3442980T/lt unknown
- 2017-04-18 CN CN201780031509.4A patent/CN109195972B/zh active Active
- 2017-04-18 CN CN202211269931.2A patent/CN115650985B/zh active Active
- 2017-04-18 AU AU2017250448A patent/AU2017250448C1/en active Active
-
2018
- 2018-10-07 IL IL262185A patent/IL262185B/en unknown
- 2018-10-15 MX MX2021013110A patent/MX2021013110A/es unknown
-
2020
- 2020-08-18 AU AU2020220079A patent/AU2020220079B2/en active Active
-
2021
- 2021-02-02 US US17/165,151 patent/US11548896B2/en active Active
- 2021-09-06 CY CY20211100784T patent/CY1124478T1/el unknown
- 2021-09-07 JP JP2021145468A patent/JP2021193108A/ja active Pending
-
2022
- 2022-06-06 AU AU2022203916A patent/AU2022203916A1/en not_active Abandoned
- 2022-11-22 US US17/992,049 patent/US20230339954A1/en not_active Abandoned
-
2023
- 2023-08-10 JP JP2023131211A patent/JP2023159230A/ja active Pending
-
2024
- 2024-12-03 US US18/967,321 patent/US20250236624A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021193108A5 (2) | ||
| JP2020503247A5 (2) | ||
| US12357603B2 (en) | Acyl sulfonamides for treating cancer | |
| AU2015328553C1 (en) | Aminopyridyloxypyrazole compounds | |
| CA3000548C (en) | Pyrimido- or pyridopyridone compound and use as a cyclin-dependent kinase inhibitor | |
| JP5292102B2 (ja) | チロシンキナーゼ調節剤としてのトリアゾロピリダジン類 | |
| JP6263193B2 (ja) | スルホキシイミン基を含んでいる５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体 | |
| Aziz et al. | Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2, 4-diones bearing heterocyclic rings as dual VEGFR-2/EGFR T790M tyrosine kinase inhibitors | |
| JP4667463B2 (ja) | チロシンキナーゼ阻害剤として適する環状ジアリールウレア | |
| JP2018503648A (ja) | ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体 | |
| US20110053931A1 (en) | Quinoline compounds and methods of use | |
| CN115803326A (zh) | Egfr抑制剂及其制备方法与在药学上的应用 | |
| JP2022532850A (ja) | ４ｈ－ピロロ［３，２－ｃ］ピリジン－４－オン化合物 | |
| JP2014525464A5 (2) | ||
| CN107949557B (zh) | 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类 | |
| JP2013530199A5 (2) | ||
| KR20140075775A (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
| EP2702055A1 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| Geuns-Meyer et al. | Discovery of N-(4-(3-(2-aminopyrimidin-4-yl) pyridin-2-yloxy) phenyl)-4-(4-methylthiophen-2-yl) phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines | |
| CA2484288A1 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| JP2017537948A5 (2) | ||
| JP6263194B2 (ja) | スルホキシイミン基を含んでいるｎ−（ピリジン−２−イル）ピリミジン−４−アミン誘導体 | |
| EA029027B1 (ru) | Замещенные имидазопиридазины | |
| Barlaam et al. | Discovery of a series of 7-azaindoles as potent and highly selective CDK9 inhibitors for transient target engagement | |
| JP2015531361A (ja) | 過剰増殖性疾患の治療に有用な置換インダゾール−ピロロピリミジン |